艾伯维Abbvie Inc （ABBV） 2019年负责任行动报告「NYSE」.pdf

1、2019ResponsibleAction ReportTable of contentsA message from our CEO .1Our company and our business .22019 highlights .3Our approach to corporate responsibility .4Making a remarkable impact for patients .7Building and supporting a diverse,.19 high-performing workforceMaking positive contributions to

2、society .27Looking ahead .37The purpose of this report is to describe our approach to corporate responsibility and our recent work to advance our responsibility priorities.2019 Responsible Action Report 1“Making a remarkable impact requires taking the long view of investment,research and development

3、 and how we can be an effective long-term partner in health and well-being.”A message from our CEOAt AbbVie,we are guided in everything we do by our desire to make a remarkable impact on the lives of patients.As we launched new treatments in immunology and oncology and continued to advance our pipel

4、ine,we also worked collaboratively with many external partners to advance long-term efforts in eliminating hepatitis C,treatments for neglected tropical diseases,evidence-based disease management,health care access and community resilience.The decision to acquire Allergan is part of our strategy to

5、ensure long-term sustainability for AbbVie and increase our ability to meet the needs of patients.Allergan brings therapeutic area leadership,diversification and resources that will help fuel continued investment in research on new treatments for debilitating and life-threatening conditions such as

6、cancer and neurodegenerative disease.The COVID-19 pandemic that emerged at the end of 2019 has challenged governments,health care providers and researchers around the world to act quickly in an effort to save lives.Like many of our peers,AbbVie has responded rapidly to requests from countries and or